The New England Comparative Effectiveness Public Advisory Council (New England CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The New England CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care.

New England CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes.

Learn more about the New England CEPAC process.

Find out how topics are selected.

All members of the New England CEPAC must meet ICER’s criteria for Conflict of Interest.

 


Next Meeting

November 18, 2016 10AM-4PM

Boston, MA

Psoriasis

The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for psoriasis.


Active Topic

Psoriasis

Plaque Psoriasis is a common disease that causes red, scaly, raised lesions on the skin, most commonly on the elbows, knees, scalp, and back. Psoriasis affects about 2% of the population and significantly decreases health-related quality of life, particularly if lesions are in areas that can affect daily functioning (e.g., the hands or soles of the feet) or affect social functioning (e.g., the face). Psoriasis is a chronic inflammatory condition that is associated with systemic diseases including psoriatic arthritis, other autoimmune diseases, the metabolic syndrome, and cardiovascular disease.

For more information on the timeline for this review and to learn about opportunities for public comment, visit the New England CEPAC Meeting page.

Interventions of interest:

Anti-TNF agents:

  • Adalimumab (Humira®, AbbVie)
  • Etanercept (Enbrel®, Amgen, Inc.)
  • Infliximab (Remicade®, Janssen)
  • Anti IL-17A agents:

  • Secukinumab (Cosentyx®, Novartis)
  • Ixekizumab (Taltz®, Eli Lilly and Co.)
  • Brodalumab (Valeant Pharmaceuticals and AstraZeneca)
  • Anti IL-12/13 agent:

  • Ustekinumab (Stelara®, Janssen)
  • Anti-PDE4 agent:

  • Apremilast (Otezla®, Celgene)
  • View materials